Par's Xalatan Generic Delayed Until 2011 Under Patent Ruling
This article was originally published in The Pink Sheet Daily
Executive Summary
Two of three Pfizer patents for the glaucoma treatment are valid, a Trenton, N.J. federal court says. If the court's ruling is affirmed on appeal, Par would lose any 180-day generic marketing exclusivity that attaches to the two valid patents.